SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
ARCA biopharma, Inc. (ABIO) .
Criteria proven by this page:
- VALUE (0/100, Fail) — the composite valuation score falls below the 60/100 threshold required to pass.
Overall SharesGrow Score: 46/100 with 2/7 criteria passed.
SharesGrow 7-Criteria Score
✓
HEALTH
100/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — ABIO
Valuation Multiples
P/E (TTM)0.0
Forward P/EN/A
PEG RatioN/A
Forward PEGN/A
P/B Ratio0.00
P/S Ratio0.00
EV/EBITDA0.0
Per Share Data
EPS (TTM)$-154.03
Book Value / Share$0.00
Revenue / Share$0.00
FCF / Share$0.00
Yields & Fair Value
Earnings YieldN/A
Dividend Yield0.00%
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2015 |
$-32.76 |
$0.00 |
$-11.45M |
- |
| 2016 |
$-32.68 |
$0.00 |
$-16.44M |
- |
| 2017 |
$-31.91 |
$0.00 |
$-18.49M |
- |
| 2018 |
$-10.31 |
$0.00 |
$-7.93M |
- |
| 2019 |
$-4.15 |
$0.00 |
$-5.48M |
- |
| 2020 |
$-2.07 |
$0.00 |
$-9.74M |
- |
| 2021 |
$-1.39 |
$0.00 |
$-19.32M |
- |
| 2022 |
$-0.69 |
$0.00 |
$-9.93M |
- |
| 2023 |
$-0.37 |
$0.00 |
$-5.34M |
- |
| 2025 |
$-154.03 |
$0.00 |
$-105.43M |
- |
